HomeCompareAAALY vs PFE

AAALY vs PFE: Dividend Comparison 2026

AAALY yields 103.62% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $6.2K in total portfolio value· pulled ahead in Year 10
10 years
AAALY
AAALY
● Live price
103.62%
Share price
$34.65
Annual div
$35.90
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$22.29
Full AAALY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AAALY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAAALYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AAALY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AAALY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AAALY
Annual income on $10K today (after 15% tax)
$8,807.48/yr
After 10yr DRIP, annual income (after tax)
$18.95/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,300.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AAALY + PFE for your $10,000?

AAALY: 50%PFE: 50%
100% PFE50/50100% AAALY
Portfolio after 10yr
$46.5K
Annual income
$13,140.50/yr
Blended yield
28.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AAALY
No analyst data
Altman Z
0.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AAALY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAAALYPFE
Forward yield103.62%6.13%
Annual dividend / share$35.90$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$43.3K$49.6K
Annual income after 10y$22.29$26,258.71
Total dividends collected$14.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AAALY vs PFE ($10,000, DRIP)

YearAAALY PortfolioAAALY Income/yrPFE PortfolioPFE Income/yrGap
1$15,881$5,180.87$9,153$693.39+$6.7KAAALY
2$20,837$3,844.71$8,593$849.25+$12.2KAAALY
3$24,653$2,357.30$8,336$1,066.78+$16.3KAAALY
4$27,682$1,303.27$8,437$1,384.80+$19.2KAAALY
5$30,304$683.83$9,013$1,875.40+$21.3KAAALY
6$32,775$349.81$10,306$2,680.72+$22.5KAAALY
7$35,246$176.79$12,820$4,101.38+$22.4KAAALY
8$37,802$88.84$17,673$6,826.70+$20.1KAAALY
9$40,493$44.53$27,543$12,591.86+$12.9KAAALY
10← crossover$43,349$22.29$49,560$26,258.71$6.2KPFE

AAALY vs PFE: Complete Analysis 2026

AAALYStock

Aareal Bank AG, together with its subsidiaries, provides financing, software products, digital solutions, and payment transaction applications for the property sector and related industries in Germany, North America, Asia Pacific, and internationally. The company operates through three segments: Structured Property Financing, Banking & Digital solutions, and Aareon. The Structured Property Financing segment offers property financing and refinancing solutions for office buildings, hotels, and shopping centers, as well as retail, logistics, residential properties, and student housing. This segment also provides deposits, registered and bearer Pfandbriefe, promissory note loans, medium-term notes, debt securities, private placements, other bonds and subordinated issues, mortgage Pfandbriefe, and public sector Pfandbriefe. The Banking & Digital solutions segment offers various services and products for the housing, commercial property, and energy and waste disposal industries. Its services include specialized banking, payment systems, and optimized business processes. The Aareon segment provides IT systems consultancy and related advisory services, enterprise resource planning systems, software solutions, hosting and software as a service, and in-house services. Aareal Bank AG was incorporated in 1923 and is headquartered in Wiesbaden, Germany.

Full AAALY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AAALY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AAALY vs SCHDAAALY vs JEPIAAALY vs OAAALY vs KOAAALY vs MAINAAALY vs JNJAAALY vs MRKAAALY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.